Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo

Author： Someya Yuka  

Publisher： Springer Publishing Company

ISSN： 0028-1298

Source： Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.377, Iss.3, 2008-05, pp. : 209-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 13, 2012-11 ,pp. : 1345-1358

Bentham Science Publishers

Access to resources Recommend Favorite

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

By Forst Thomas   Pfützner Andreas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 101-110

Informa Healthcare

Access to resources Recommend Favorite

Docking Study of Novel Pyrrolidine Derivatives as Potential Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 12, Iss. 4, 2015-05 ,pp. : 284-291

Bentham Science Publishers

Access to resources Recommend Favorite

Investigating the Contributions of Residues to Dipeptidyl Peptidase-IV Inhibitor Binding by Molecular Dynamics Simulation

By  

Letters in Drug Design & Discovery, Vol. 11, Iss. 7, 2014-08 ,pp. : 886-893

Bentham Science Publishers

Access to resources Recommend Favorite

Human pharmacokinetic profiling of the dipeptidyl peptidase‐IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling

By  

Biopharmaceutics And Drug Disposition, Vol. 36, Iss. 3, 2015-04 ,pp. : 148-162

John Wiley & Sons Inc

Access to resources Recommend Favorite